The present invention provides methods and devices for treating endovascular disease. Vibrational energy is delivered to change compliance and increase permeability at the treatment area. To improve clinical outcomes, one or more therapeutic drugs may be delivered to the treatment area.

According to some embodiments there is provided a method for controlling a treatment effect on blood vessel tissue during an ultrasonic treatment, the method comprising positioning an ultrasonic transducer device in the blood vessel lumen; controlling a treatment effect by controlling fluid flow, wherein controlling comprises deploying a fluid restrictor at a location relative to the transducer effective to block at least a portion of fluid flowing upstream, downstream or adjacent the transducer. According to some embodiments there is provided an ultrasonic transducer device sized for placement in a body lumen, and comprising a fluid restrictor effective to block at least a portion of fluid flowing upstream, downstream or adjacent the transducer. In some embodiments, the fluid is blood.

A method and apparatus for treating a clot in the blood vessel of a patient, and particularly the treatment of a pulmonary embolism is disclosed. The treatment includes restoring flow through the clot followed by clot removal, either partially or substantially completely. The clot treatment device is expandable into the blood vessel and may contain radial extensions that assist in restoring flow as well as in removing clot material.

A medical device with an expandable element and expandable tubular sleeve surrounding at least a portion of the expandable element which influences the rate, shape and/or force required to expand the expandable element and methods for use in a body lumen are provided.

Provided are a treatment method, a separation method, and a filter assembly capable of preventing so-called “Blue Toe syndrome” which is so-called cholesterol crystal embolism of which a fat-soluble compound such as cholesterol crystals generated during dilation of a stenosed site causes clogging in glomeruli of peripheral capillaries or kidney, acute renal failure, and the like. Cholesterol crystals generated from plaque during use of a balloon catheter are taken out of the body and removed using a centrifugal separation device or a filter, and usable living cells are returned to the body to reduce blood transfusion and reduce cholesterol crystal embolism.

A method and apparatus for treating a clot in the blood vessel of a patient, and particularly the treatment of a pulmonary embolism is disclosed. The treatment includes restoring flow through the clot followed by clot removal, either partially or substantially completely. The clot treatment device is expandable into the blood vessel and may contain radial extensions that assist in restoring flow as well as in removing clot material.

Systems for imparting pulsatile energy to cardiovascular tissue are provided. Aspects of the systems include a console assembly comprising a potential source, a manifold assembly operably connected to an output of the console assembly, wherein the manifold assembly comprises an oscillator configured to generate pulse energy from energy transmitted from the potential source and a catheter assembly operably connected to an output of the manifold assembly. Catheter assemblies of the present invention include a connector operably connecting the catheter assembly to the manifold assembly and configured to transduce a first pulse energy generated by the manifold assembly to a second pulse energy, a catheter comprising a fluidic passage operably connected to the output of the connector and configured to transmit the second pulse energy and a heart-tissue-conforming element configured to receive the second pulse energy transmitted through the fluidic passage of the catheter to apply pulsatile energy to cardiovascular tissue. Also provided are methods for imparting pulsatile energy to cardiovascular tissue, e.g., deploying a system so that a heart-tissue-conforming element of the system is adjacent to cardiovascular tissue and engaging the system in a manner that the heart-tissue-conforming element imparts energy to the cardiovascular tissue. In addition, standalone catheter assemblies as well as kits comprising components of the systems described herein are provided. The systems, assemblies, methods and kits find use in a variety of different applications, including balloon angioplasty applications or other catheter-based therapies or treatments.

A system includes a catheter including an elongated carrier, a balloon about the carrier in sealed relation thereto, the balloon being arranged to receive a fluid therein that inflates the balloon, and first and second electrodes within the balloon arranged to carry a voltage there-across including an initial high electrical voltage at an initial low current. The initial high electrical voltage causes an electrical arc to form across the first and second electrodes within the balloon. The electrical arc causes a gas bubble within the liquid, a high current to flow through the first and second electrodes, a decrease in the initial high electrical voltage, and a mechanical shock wave within the balloon. The system further includes a power source that provides the first and second electrodes with a drive voltage that creates the initial high electrical voltage at the initial current and that terminates the drive voltage in response to the decrease in the initial high electrical voltage.

A pharmaceutical composition and a method of using the pharmaceutical composition for the treatment of thrombosis are provided. The pharmaceutical composition can include a mixture of proteolytic enzymes, and optionally, additional compounds. The pharmaceutical composition can include an antiaggregatory or anti-thrombotic compound, such as Lisini racemici acetylsalicylase. The method can include administering the pharmaceutical composition to a patient in need thereof, including administration of the pharmaceutical composition to a thrombus until the thrombus is dissolved. The method can also include administering one or more balloon catheters to the patient.

A stent retriever assembly having a proximal end and a distal end and including a mesh tube having a distal and proximal end and being connected to a first wire. Also, a blood-porous fragment guard is at the distal end of the mesh tube and has a central hub and extending radially and proximally from the central hub. Further, a second wire is connected to the central hub, and when this second wire is pulled proximally relative to the first wire, the hub is pulled proximally, which thereby causes the fragment guard to deploy in expanded form.